HOLOGIC
24.3.2022 13:02:08 CET | Business Wire | Press release
Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company primarily focused on improving women’s health, opened its new Innovation Center today in Aix-en-Provence, France. This announcement follows Hologic’s 2019 acquisition of Aix-en-Provence-based SuperSonic Imagine and further demonstrates Hologic’s commitment to the EMEA region. The new commercial office, training and research and development facility will support Hologic’s ultrasound, interventional and surgical solutions across the continuum of breast health care.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220324005088/en/
“Hologic is a global champion for women’s health and brings innovative technologies to healthcare professionals helping them detect, diagnose and treat illnesses and health conditions earlier and more effectively,” said Antoine Bara, General Manager of Hologic France. “The significant investment being made in France is another example of Hologic’s relentless commitment to innovation and its mission to improve the health and well-being of 3.9 billion woman globally.”
The facility also will serve as Hologic’s new French headquarters. They will operate as a hub to bring new innovations to market, expanding access to new technologies in the European market, and building the expertise of healthcare professionals. This investment will bring to life Hologic's ambition to improve women’s health globally by developing innovative products and services that drive certainty in outcomes for patients and providers.
Hologic is a champion of women’s health and recently launched the Hologic Global Women’s Health Index in France. The Index is a multiyear effort that measures five dimensions of health which explain 80% of women’s life expectancy: Preventive Care, Basic Needs, Opinions of Health & Safety, Individual Health, and Emotional Health. It provides a global, and comprehensive data set from the lived experiences of women and girls to guide world leaders, policymakers, and women. The data set helps to understand the issues and promote action to improve the quality of life and life expectancy of women worldwide. It represents the knowledge, attitudes, and behaviors of 2.5 billion women aged 15+. More information on the Index and specific data for France is available on request.
For more information on Hologic, visit www.hologic.fr .
About Hologic, Inc.
Hologic, Inc. is a global medical technology innovator primarily focused on improving women’s health and well-being through early detection and treatment. Its advancements include creation of the world’s first commercial 3D mammography system to detect breast cancer; leadership in testing for cervical cancer, sexually transmitted infections, respiratory illnesses and the virus that causes COVID-19; and minimally invasive surgical technologies for uterine fibroids and abnormal uterine bleeding.
Forward-Looking Statements
This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.
This information is not intended as a product solicitation or promotion where such activities are prohibited. For specific information on what products are available for sale in a particular country, please contact a local Hologic sales representative or write to France@hologic.com .
SOURCE: Hologic, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005088/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 14:48:00 CEST | Press release
Rapid growth shows strong demand for a new trading model where users can make market predictions without risking their own capital Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong
Klarna Submits Application for U.S. Banking License6.7.2026 14:30:00 CEST | Press release
Klarna (NYSE: KLAR), the global digital bank and flexible payments provider, today announced it has submitted applications to the Utah Department of Financial Institutions and the Federal Deposit Insurance Corporation (FDIC) to establish Klarna Bank USA, a proposed Utah-chartered industrial bank. Klarna has operated as a licensed bank in Europe since 2017 and serves U.S. customers through valued partner banks. Since 2019, Klarna has provided Americans with access to over $91.3 billion in responsible credit, saving them more than $5.1 billion in interest compared to revolving credit card debt. Today, 30 million Americans use Klarna each year, and hundreds of thousands of merchants rely on Klarna to grow their businesses. "Banking is built on trust," said Sebastian Siemiatkowski, co-founder and CEO of Klarna. "We've seen firsthand the appetite for a fairer, more transparent approach in the U.S., and our own banking license is the natural next step, giving customers tools to borrow respon
IQM Quantum Computers Acquires Assets of Quantistry GmbH to Bridge the Gap Between Quantum Algorithms and Solutions for Industrial Enterprises6.7.2026 14:00:00 CEST | Press release
This is a strategic asset acquisition comprising proprietary software and intellectual property of Quantistry GmbH, a pioneer in cloud-native, AI-powered chemical and materials simulation By integrating Quantistry’s advanced simulation platform with IQM’s leading quantum computing hardware, IQM will deliver an end-to-end quantum-classical applications development platform and algorithm libraries powered by a user-friendly native-AI computing environment The transaction secures a critical enterprise software layer that accelerates IQM’s application roadmap, enabling industrial enterprises to develop quantum application proof-of-concepts and scale them over time, backed by a reliable, long-term quantum roadmap It also enhances IQM’s ability to deepen domain expertise across specific industry verticals Quantistry’s core quantum chemistry and machine learning engineering team will join IQM, strengthening the company’s ability to deepen relationships with tier-one industrial enterprises acr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
